OpenAlex
PricingAboutJobs
Log inGet started
Work

Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

HTML

Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2020.38.4_suppl.133
Authors: Eyal Meiri, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Sagun Shrestha, Eugene R. Ahn, Olufunlayo Osayameh, Venu Perla, Richard L. Schilsky
Institutions: Cancer Treatment Centers of America, Medical University of South Carolina, Duke Medical Center, American Society of Clinical Oncology
Language: English

Topic: Colorectal Cancer Treatments and Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: pembrolizumab, colorectal cancer, immune checkpoint inhibitors, anti-PD-1 therapy, disease control rate, progression-free survival, overall survival, treatment safety, advanced colorectal cancer, genomic profiling, targeted therapy, biomarker-guided therapy, patient-reported outcomes, quality of life
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2947703016
Cites:
Cited by: 57
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security